Bicycle Therapeutics Ltd (BCYC)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

B900 BABRAHAM RESEARCH CAMPUS CAMBRIDGE, UNITED KINGDOM CB22 3AT

Bicycle Therapeutics Ltd. operates as a biotechnology company. The Company offers a platform that combines small molecules and biopharmaceuticals to create drugs. Bicycle Therapeutics serves patients in the United Kingdom and the United States.

Data as of 2020-08-01
Market Cap285.785 Million Shares Outstanding18.088 Million Avg 30-day Volume73.979 Thousand
P/E Ratio Dividend Yield EPS-2.33
Price/Sales40.687 Price cash flow ratio Price free cash flow ratio67.4
Book Value4.52 Price to Tangible Book3.59 Alpha0.05
Short Interest Ratio % Short Interest to Float R-squared0.024999
BETA-0.560352 52-week High/Low20.1 / 6.2401 Stddev0.218377
View SEC Filings from BCYC instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 1 (0.07%)
13F Filers holding this stock: 16 7 (0.46%)
Aggregate 13F shares on 03/31/2020: 5.977 Million 2.433 Million
Aggregate 13F shares on 12/31/2019: 5.902 Million 2.446 Million
Percent change: 1.28% -0.51%
Funds creating new positions: 5 2
Funds Adding to an existing position: 3 1
Funds closing out their position:
Funds reducing their position: 3 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BCYC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BCYC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GLAXOSMITHKLINE PLC

  • 10% Owner
4,626,389 2020-07-24 0

LEGAULT PIERRE

  • Director
21,480 2020-07-21 1

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • FORMER 10% OWNERFORMER 10% OWNER
1,181,258 2020-06-30 0

KENDER RICHARD N

  • Director
0 2020-06-18 2

JORDAN VERONICA GH

  • Director
288,694 2020-06-05 3

HAU BOSUN

  • Director
0 2020-06-04 0

WINTER GREGORY PAUL

  • Director
163,927 2020-04-14 2

CROCKETT NIGEL CHIEF BUSINESS OFFICER

  • Officer
0 2020-02-21 5

BINGHAM KATE

  • Director
0 2020-01-02 1

KALOWSKI LEE PRESIDENT AND CFO

  • Officer
0 2020-01-02 1

LEE KEVIN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-02 1

KEEN NICHOLAS CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-01-02 1

SKYNNER MICHAEL CHIEF OPERATING OFFICER

  • Officer
0 2020-01-02 1

BOURQUE JANICE

  • Director
0 2020-01-02 2

SVLSF V, LLC

SV LIFE SCIENCES FUND V LP

SV LIFE SCIENCES FUND V (GP), LP

SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.

  • 10% Owner
3,444,833 2019-05-28 0

LEONE PETER BRIAN CHIEF BUSINESS OFFICER

  • Officer
0 2019-05-28 0

VERTEX GLOBAL HEALTHCARE FUND I PTE LTD.

  • 10% Owner
1,621,168 2019-05-28 0

ANSTEY MICHAEL

  • Director
1,751,437 2019-05-28 0

HARLAND DEBORAH

  • Director
1,915,275 2019-05-28 0

NG CAROLYN

  • Director
2,192,597 2019-05-28 0

CAMBRIDGE INNOVATION CAPITAL (JERSEY) LTD

  • 10% Owner
1,751,437 2019-05-28 0

TYBOURNE CAPITAL MANAGEMENT (HK) LTD

TYBOURNE CAPITAL MANAGEMENT LTD

TYBOURNE KESARI LTD

KRISHNAN VISWANATHAN

AQUILA INVESTMENTS IV

  • 10% Owner
1,957,961 2019-05-28 0

AQUILA INVESTMENTS IV

  • 10% Owner
0 2019-05-22 0

TYBOURNE CAPITAL MANAGEMENT (HK) LTD

TYBOURNE CAPITAL MANAGEMENT LTD

TYBOURNE KESARI LTD

KRISHNAN VISWANATHAN

  • 10% Owner
0 2019-05-22 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments